184 related articles for article (PubMed ID: 26024761)
1. Chemically Programmed Bispecific Antibody Targeting Legumain Protease and αvβ3 Integrin Mediates Strong Antitumor Effects.
Liu Y; Goswami RK; Liu C; Sinha SC
Mol Pharm; 2015 Jul; 12(7):2544-50. PubMed ID: 26024761
[TBL] [Abstract][Full Text] [Related]
2. Multiple catalytic aldolase antibodies suitable for chemical programming.
Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
[TBL] [Abstract][Full Text] [Related]
3. Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro.
Goswami RK; Bajjuri KM; Forsyth JS; Das S; Hassenpflug W; Huang ZZ; Lerner RA; Felding-Habermann B; Sinha SC
Bioconjug Chem; 2011 Aug; 22(8):1535-44. PubMed ID: 21774545
[TBL] [Abstract][Full Text] [Related]
4. Targeting cell surface alpha(v)beta(3) integrin increases therapeutic efficacies of a legumain protease-activated auristatin prodrug.
Liu Y; Bajjuri KM; Liu C; Sinha SC
Mol Pharm; 2012 Jan; 9(1):168-75. PubMed ID: 22044266
[TBL] [Abstract][Full Text] [Related]
5. Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.
Gavrilyuk JI; Wuellner U; Barbas CF
Bioorg Med Chem Lett; 2009 Mar; 19(5):1421-4. PubMed ID: 19181522
[TBL] [Abstract][Full Text] [Related]
6. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
7. An efficient chemical approach to bispecific antibodies and antibodies of high valency.
Gavrilyuk JI; Wuellner U; Salahuddin S; Goswami RK; Sinha SC; Barbas CF
Bioorg Med Chem Lett; 2009 Jul; 19(14):3716-20. PubMed ID: 19497743
[TBL] [Abstract][Full Text] [Related]
8. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin.
Goswami RK; Liu Y; Liu C; Lerner RA; Sinha SC
Mol Pharm; 2013 Feb; 10(2):538-43. PubMed ID: 23102054
[TBL] [Abstract][Full Text] [Related]
10. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
[TBL] [Abstract][Full Text] [Related]
11. Generation and Characterization of a Bispecific Antibody Targeting Both PD-1 and c-MET.
Wu Y; Yu M; Sun Z; Hou W; Wang Y; Yuan Q; Mo W
Protein Pept Lett; 2018 Feb; 24(12):1105-1112. PubMed ID: 29046141
[TBL] [Abstract][Full Text] [Related]
12. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
13. Autocrine pro-legumain promotes breast cancer metastasis via binding to integrin αvβ3.
Liu C; Wang J; Zheng Y; Zhu Y; Zhou Z; Liu Z; Lin C; Wan Y; Wen Y; Liu C; Yuan M; Zeng YA; Yan Z; Ge G; Chen J
Oncogene; 2022 Aug; 41(34):4091-4103. PubMed ID: 35854065
[TBL] [Abstract][Full Text] [Related]
14. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
[TBL] [Abstract][Full Text] [Related]
15. Legumain Functions as a Transient TrkB Sheddase.
Holzner C; Böttinger K; Blöchl C; Huber CG; Dahms SO; Dall E; Brandstetter H
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982466
[TBL] [Abstract][Full Text] [Related]
16. Breaking the one antibody-one target axiom.
Guo F; Das S; Mueller BM; Barbas CF; Lerner RA; Sinha SC
Proc Natl Acad Sci U S A; 2006 Jul; 103(29):11009-14. PubMed ID: 16822849
[TBL] [Abstract][Full Text] [Related]
17. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity.
Choi HJ; Kim YJ; Lee S; Kim YS
Mol Cancer Ther; 2013 Dec; 12(12):2748-59. PubMed ID: 24132142
[TBL] [Abstract][Full Text] [Related]
18. Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis.
Zhao T; Liu Y; Hao Y; Zhang W; Tao L; Wang D; Li Y; Liu Z; McKenzie EA; Zhao Q; Diao A
Invest New Drugs; 2021 Apr; 39(2):337-347. PubMed ID: 32978718
[TBL] [Abstract][Full Text] [Related]
19. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
[TBL] [Abstract][Full Text] [Related]
20. Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells.
Rozan C; Cornillon A; Pétiard C; Chartier M; Behar G; Boix C; Kerfelec B; Robert B; Pèlegrin A; Chames P; Teillaud JL; Baty D
Mol Cancer Ther; 2013 Aug; 12(8):1481-91. PubMed ID: 23757164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
